RFS for participants according to peri-HCT MRD, NPM1 comutation at initial diagnosis, and randomization arm. (A) NPM1 comutation; gilteritinib vs placebo. (B) NPM1 comutation; peri-HCT MRD positive; gilteritinib vs placebo. (C) NPM1 comutation; peri-HCT MRD negative; gilteritinib vs placebo. (D) NPM1 wild type; gilteritinib vs placebo. (E) NPM1 wild type; peri-HCT MRD positive; gilteritinib vs placebo. (F) NPM1 wild type; peri-HCT MRD negative; gilteritinib vs placebo. HR, hazard ratio.